TY - JOUR
T1 - Involvement of the α1D-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats
AU - Kikuchi-Utsumi, Kazue
AU - Ishizaka, Mami
AU - Matsumura, Nobuko
AU - Watabe, Masahiko
AU - Aoyama, Koji
AU - Sasakawa, Nobuyuki
AU - Nakaki, Toshio
PY - 2013/8
Y1 - 2013/8
N2 - Methamphetamine (METH) is a psychostimulant that damages nigrostriatal dopaminergic terminals, primarily by enhancing dopamine and glutamate release. α1-adrenergic receptor (AR) subtype involved in METH-induced neurotoxicity in rats was investigated using selective α1-AR antagonists. METH neurotoxicity was evaluated by (1) measuring body temperature; (2) determining tyrosine hydroxylase (TH) immunoreactivity levels; (3) examining levels of dopamine and its metabolites; and (4) assessing glial fibrillary acidic protein (GFAP) and microglial immunoreactivity in the striatum. METH caused a decrease in dopamine and TH levels and induced hyperthermia which is an exacerbating factor of METH neurotoxicity. Concurrently, METH increased GFAP expression and the number of activated microglia. Pretreatment with prazosin, a nonselective α1-AR antagonist, completely abolished METH-induced decrease in both dopamine and TH and caused a partial reduction in hyperthermia. Prazosin also prevented METH-induced increase in both GFAP expression and the number of activated microglia. In vivo microdialysis analysis revealed that prazosin, however, does not alter the METH-induced dopamine release in the striatum. The neuroprotective effects of prazosin could be mimicked by a selective α1D antagonist, BMY 7378, but not by selective α1A or α1B antagonists. These results suggest that the α1D-AR is involved in METH-induced hyperthermia and neurotoxicity in rats.
AB - Methamphetamine (METH) is a psychostimulant that damages nigrostriatal dopaminergic terminals, primarily by enhancing dopamine and glutamate release. α1-adrenergic receptor (AR) subtype involved in METH-induced neurotoxicity in rats was investigated using selective α1-AR antagonists. METH neurotoxicity was evaluated by (1) measuring body temperature; (2) determining tyrosine hydroxylase (TH) immunoreactivity levels; (3) examining levels of dopamine and its metabolites; and (4) assessing glial fibrillary acidic protein (GFAP) and microglial immunoreactivity in the striatum. METH caused a decrease in dopamine and TH levels and induced hyperthermia which is an exacerbating factor of METH neurotoxicity. Concurrently, METH increased GFAP expression and the number of activated microglia. Pretreatment with prazosin, a nonselective α1-AR antagonist, completely abolished METH-induced decrease in both dopamine and TH and caused a partial reduction in hyperthermia. Prazosin also prevented METH-induced increase in both GFAP expression and the number of activated microglia. In vivo microdialysis analysis revealed that prazosin, however, does not alter the METH-induced dopamine release in the striatum. The neuroprotective effects of prazosin could be mimicked by a selective α1D antagonist, BMY 7378, but not by selective α1A or α1B antagonists. These results suggest that the α1D-AR is involved in METH-induced hyperthermia and neurotoxicity in rats.
KW - α-adrenergic receptor
KW - Dopamine
KW - Glial fibrillary acidic protein
KW - Methamphetamine
KW - Microglia
KW - Neurotoxicity
UR - http://www.scopus.com/inward/record.url?scp=84879800506&partnerID=8YFLogxK
U2 - 10.1007/s12640-012-9369-9
DO - 10.1007/s12640-012-9369-9
M3 - 記事
C2 - 23283760
AN - SCOPUS:84879800506
SN - 1029-8428
VL - 24
SP - 130
EP - 138
JO - Neurotoxicity Research
JF - Neurotoxicity Research
IS - 2
ER -